An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective
PHASE3CompletedINTERVENTIONAL
Enrollment
20
Participants
Timeline
Start Date
May 31, 2015
Primary Completion Date
December 31, 2017
Study Completion Date
March 20, 2018
Conditions
Rheumatoid Arthritis
Interventions
DRUG
tofacitinib
oral tofacitinib will be taken 2 times daily
Trial Locations (1)
33180
AARDS Research, Inc., Aventura
All Listed Sponsors
lead
Norman B. Gaylis, MD
OTHER
NCT02566967 - An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve Low Disease Activity (LDA) or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective | Biotech Hunter | Biotech Hunter